Novartis CEO Shrugs Off Paltry Price For Flu Vaccines Unit
This article was originally published in PharmAsia News
Novartis says the $275 million received from Australia’s CSL for its influenza unit was not a great price but was “the best” on offer, allowing the Swiss group to fully exit vaccines and continue moving ahead on its strategic plan.
You may also be interested in...
Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.